Sanjiv Harpavat, MD, PhD
I am a pediatric gastroenterologist with special interests in neonatal cholestasis (abnormal jaundice in newborns and infants), genetic causes of liver disease such as progressive familial intrahepatic cholestasis and Wilson disease, liver transplantation, and non-alcoholic fatty liver disease. Our clinical and translational research focuses on the serious liver condition biliary atresia (BA). I lead an NIH-funded multi-hospital screening initiative for BA, as well as clinical trials of novel medications to help improve outcomes in BA after the Kasai operation.
Freeman AJ, Ng VL, Harpavat S, Hrycko A, Apted Z, Bulut P, Leong T, Karpen SJ. Level of γ-glutamyltransferase in 2-Year-old Children With Biliary Atresia Associates With Progression of Portal Hypertension. Clinical Gastroenterology and Hepatology 2017 Jul;15(7):1133-1135.
Harpavat S, Garcia-Prats JA, Shneider BL. Newborn Bilirubin Screening for Biliary Atresia. The New England Journal of Medicine 2016 Aug;375(6):605-6.
Harpavat S, Ramraj R, Finegold MJ, Brandt ML, Hertel PM, Fallon SC, Shepherd RW, Shneider BL. Newborn Direct or Conjugated Bilirubin Measurements As a Potential Screen for Biliary Atresia. Journal of Pediatric Gastroenterology and Nutrition 2016 Jun;62(6):799-803.
Tessier ME, Harpavat S, Shepherd RW, Hiremath GS, Brandt ML, Fisher A, Goss JA. Beyond the Pediatric end-stage liver disease system: solutions for infants with biliary atresia requiring liver transplant. World Journal of Gastroenterology 2014 Aug;20(32):11062-8.
Harpavat S, Finegold MJ, Karpen SJ. Patients with biliary atresia have elevated direct/conjugated bilirubin levels shortly after birth. Pediatrics 2011 Dec;128(6):e1428-33.
* Texas Children's Hospital physicians' licenses and credentials are reviewed prior to practicing at any of our facilities. Sections titled From the Doctor, Professional Organizations and Publications were provided by the physician's office and were not verified by Texas Children's Hospital.